This subcutaneous drug is indicated for growth failure in children with severe primary IGF-I deficiency and is approved for long-term therapy. It is expensive and inpatient use will be rare. Classified as non-formulary, not stocked. Defer initiation until after discharge, patient should use home supply.
Add Formweb to your mobile device
Reviewed: January 23, 2007
This subcutaneous drug is indicated for growth failure in children with severe primary IGF-I deficiency and is approved for long-term therapy. It is expensive and inpatient use will be rare. Classified as non-formulary, not stocked. Defer initiation until after discharge, patient should use home supply.